retatrutide triple agonist weight loss trial New Phase 3 data just dropped 👀 Eli Lilly's reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats First phase 3 data for

Ottenwalder H, Simon P

Integrins: sensors of extracellular matrix and modulators of cell function

Long-term GLP-1 use (12 months and beyond) is increasingly supported by real-world evidence showing sustained weight loss and improved metabolic markers

Hormone Replacement Therapy is used to add the needed estrogen to our bodies which helps prevent additional fat from being added, but what to do for the existing fat that needs to go

DSIP (, -) , , , -

En los ltimos aos, el mundo de la medicina ha observado un avance significativo en el tratamiento de la obesidad y el manejo del peso corporal gracias al desarrollo de los anlogos de GLP-1 (a-GLP1 en adelante)